HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Coccidioidomycosis — Clinical Guidelines

Overview

Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic fungal infection endemic to parts of the southwestern United States and other regions in the Western Hemisphere 2 3.

Diagnosis

Key Diagnostic Criteria: Residence in or recent travel to endemic areas is crucial 2 3.

Recommended Tests: Serological tests (e.g., complement fixation, immunodiffusion) and nucleic acid amplification tests (NAAT) are commonly used 2.

Testing Variability: Testing practices vary significantly among healthcare facilities and providers, with 2.8% of CAP patients tested for coccidioidomycosis in Arizona 1.

Management

First-Line Treatment for Acute Pulmonary Infection: Most cases resolve without antifungal therapy; however, for symptomatic patients, first-line treatment includes:

- Fluconazole: Typically not recommended for primary treatment due to lower efficacy compared to other agents 2. - Amphotericin B: Used for severe or refractory cases 2. - Itraconazole: Considered for less severe cases 2.

Adjunctive Treatments: For chronic or disseminated disease, adjunctive treatments may include:

- Fluconazole: Higher doses for chronic forms 2. - Amphotericin B deoxycholate or Lipid-based formulations: For severe or refractory cases 2.

Special Populations

Pregnancy: Specific management guidelines are not detailed in the provided abstracts 2 3.

Pediatrics: No specific recommendations provided in the abstracts 2 3.

Elderly: No distinct guidelines noted for elderly patients in the abstracts 2 3.

Comorbidities: Management considerations for patients with comorbidities are not explicitly addressed 2 3.

Key Recommendations

Consider Testing for Coccidioidomycosis in CAP Patients from Endemic Areas: Given the variability in testing practices, clinicians should consider testing CAP patients with recent travel or residence in endemic regions 1 (Evidence: Moderate).

Antifungal Therapy is Generally Not Necessary for Asymptomatic or Mild Pulmonary Coccidioidomycosis: Treatment decisions should be individualized based on clinical presentation 2 (Evidence: Strong).

Use Amphotericin B for Severe or Refractory Cases: For patients with severe or refractory disease, amphotericin B is recommended 2 (Evidence: Strong).

References

1 Khan MA, Brady S, Komatsu KK. Testing for coccidioidomycosis in emergency departments in Arizona. Medical mycology 2018. link 2 Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE et al.. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016. link 3 Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE et al.. Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016. link

Coccidioidomycosis